Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526872 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL730334 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL1095622 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL28358020 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10880891 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL5537012 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL1096441 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL6945069 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10882065 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 | |
| SCHEMBL10878345 | 1.00 | DNM1 (0.50) | DNM1USP2SPHK1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116026939-A | Octadecyloxy ethanol process control detection method | 欣凯医药化工中间体（上海）有限公司 | 2023-04-28 | — | — | CN | claimed |
| EP-1873136-A1 | Method for manufacturing alkyl and aryl ethers | Archimica GmbH (DE) | 2008-01-02 | — | — | EP | claimed |
| US-7034014-B2 | New derivatives of cidofovir, adefovir, cyclic cidofovir or tenofovir made by forming phosphonate ester with an alcohol such as alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol; e.g. 1-O-octadecylpropanediol-3-cidofovir; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-25 | — | — | US | claimed |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2025-06-26 | — | — | US | disclosed |
| EP-4518869-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ViroVet NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024159117-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023214017-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | VIROVET NV (BE) | 2023-11-09 | — | — | WO | disclosed |
| EP-4228685-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116322759-A | Phospholipid compounds and uses thereof | 吉利德科学公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116026939-A | Octadecyloxy ethanol process control detection method | 欣凯医药化工中间体（上海）有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-0837630-A4 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | UNIV CALIFORNIA (US) | 1998-11-25 | — | — | EP | disclosed |
| EP-0837630-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1996039831-A1 | PRODRUGS OF PHARMACEUTICALS WITH IMPROVED BIOAVAILABILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0417606-A2 | Method of making highly adsorptive copolymers | DOW CORNING CORPORATION (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0025720-B1 | PROCESS FOR THE MANUFACTURE OF MIXED PHOSPHORIC ACID ESTER COMPOSITIONS AND PLASTICISED POLYMERS CONTAINING THEM | FMC Corporation (US) | 1986-02-26 | — | — | EP | disclosed |
| US-4542219-A | ANTITUMOR, AGRICULTURAL FUNGICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| EP-0061872-B1 | ETHYLENEGLYCOL DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-08-07 | — | — | EP | disclosed |
| EP-0061872-A1 | Ethyleneglycol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-10-06 | — | — | EP | disclosed |
| EP-0025720-A1 | Process for the manufacture of mixed phosphoric acid ester compositions and plasticised polymers containing them | FMC Corporation (US) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205257-A1 | CYCLIC CIDOFOVIR OR A PRODRUG THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF AFRICAN SWINE FEVER | ATIC, PIGS, TYMP | DNM1 2862/4885USP2 3407/4885SPHK1 1148/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | DNM1 2561/4885USP2 1686/4885SPHK1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.